CorTec GmbH, a neurotechnology company based in Freiburg, Germany, has received FDA Breakthrough Device Designation for its Brain Interchange system for use in stroke rehabilitation—the first brain-computer interface designation worldwide for stroke motor rehabilitation. The designation facilitates medical device development through prioritized and more interactive FDA engagement. CorTec’s Brain Interchange system combines neural signal recording with adaptive stimulation in a closed-loop platform, currently being evaluated in an FDA-approved study at the University of Washington in Seattle, marking the first clinical investigation of a fully implantable, wireless BCI system for stroke rehabilitation in humans.
Clinical Need and Impact
Stroke represents a significant health burden globally, with approximately 9 million ischemic strokes occurring yearly, including an estimated 1.7 million cases in the United States and Europe. Over 80% of stroke patients experience upper-limb impairment, and approximately 50% remain permanently disabled despite standard rehabilitation. For chronic stroke patients with moderate-to-severe motor deficits whose recovery has plateaued after conventional therapy, no approved implantable treatment currently exists.
Clinical Evidence
The designation is supported by robust clinical evidence. Following FDA 510(k) clearance for cortical mapping electrodes in 2019 and successful first-in-human beta-phase–locked closed-loop stimulation in a feasibility study at the University of Washington in 2023, CorTec received IDE approval in 2024. The first two patients were implanted at Harborview Medical Center in Seattle in July 2025 and February 2026, with the first patient showing “meaningful neurological improvement, including recovery of upper-limb motor function that had previously plateaued with conventional therapy.” The Brain Interchange system demonstrated more than 500 days of continuous stability, as reported in a peer-reviewed publication in Nature Scientific Data, and is being evaluated in an FDA-registered epilepsy study at Mayo Clinic. CorTec is advancing the platform as a flexible, adaptive technology with potential applications beyond stroke, including epilepsy, paralysis, and depression.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/04/08/3270076/0/en/CorTec-Receives-FDA-Breakthrough-Device-Designation-for-Its-Brain-Interchange-System-in-Stroke-Rehabilitation-the-First-BCI-Worldwide-Designated-for-Stroke-Motor-Rehabilitation.html